Acadia Pharmaceuticals (ACAD) PT Lowered to $42 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Jay Olson lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $42.00 (from $53.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
